Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab + chemotherapy ± bevacizumab in locally advanced nasopharyngeal carcinoma (Phase II)
ChiCTR2400084566Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in nasopharyngeal carcinoma (NPC) (2 cohorts), sponsored by Sichuan Cancer Hospital. Primary endpoint: Complete response rate. Started May 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400084566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084566.